Healio (9/15, Gawel) reports a meta-analysis of more than 50 clinical trials and observational studies presented at the American Neurological Association Annual Meeting 2025 found that the “risks for developing Alzheimer’s disease can increase or decrease depending on when women begin hormone replacement therapy.” Patients in the meta-analysis included “women who used estrogen alone, estrogen and progestin, or estrogen and a selective estrogen receptor modulator after menopause, as well as those who took a placebo or did not receive any treatment.” Researchers observed a “38% increase in risk for Alzheimer’s disease among women who began hormone replacement therapy at age 65 years or older, especially among those who used progestin.” Meanwhile, “women who began therapy around the time of their menopause saw a 22% reduction in risk, based on data from 45 observational studies of real-world outcomes. This increased to a 32% reduction for those who began within 5 years of menopause, based on an analysis of the observational studies and the randomized controlled trials.”
Related Links:
— “Hormone replacement therapy timing linked to Alzheimer’s disease risks,”Richard Gawel, Healio , September 15, 2025